Monopar Therapeutics
MNPR· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +196.8% in FY2025
Chandler D. Robinson, MD is the CEO of Monopar Therapeutics and was paid $10.6M in FY2025 (Dec), up 829%.
Pay$100 in the stock at the end of FY21 → $407
Executives3
See all- 1Chandler D. Robinson, MDChief Executive Officer and DirectorFY2025
- 2Andrew CittadineChief Operating OfficerFY2025
- 3Quan VuChief Financial Officer, Secretary, and TreasurerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allMonopar Therapeutics paid its 3 named executives $17.4M in total in FY2025 (Dec). CEO Chandler D. Robinson, MD was paid $10.6M of that.
| Name | |||
|---|---|---|---|
| Chandler D. Robinson, MDChief Executive Officer and Director | |||
| Andrew CittadineChief Operating Officer | |||
| Quan VuChief Financial Officer, Secretary, and Treasurer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Monopar Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board1
See all- Arthur J. Klausner, MBADirector · 7 yr on the boardIndependentAudit, Compensation, Corporate Governance and Nominating (Chair)—Paid as an executive
The board of the latest proxy (FY2024).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 30, 2026 | FY2025 |
| Annual report | 10-K | Mar 27, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 30, 2025 | FY2024 |
| Annual report | 10-K | Mar 31, 2025 | FY2024 |
| Proxy statement | DEF 14A | Jul 22, 2024 | FY2023 |
| Annual report | 10-K | Mar 28, 2024 | FY2023 |
